<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: In a previous study, we showed that experimentally induced gastroduodenal-<z:e sem="disease" ids="C0017168,C0559234" disease_type="Disease or Syndrome;Finding" abbrv="">esophageal reflux</z:e> in mice treated with a carcinogen can result in <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> and Barrett-associated <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Since we have shown that most Barrett-associated <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> in human beings have lost the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor gene p27, we sought to determine whether <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> would be more likely to develop in p27 knockout mice than in p27 heterozygous or p27 <z:mp ids='MP_0002169'>wild type</z:mp> mice </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Three groups of mice were treated by esophagojejunostomy resulting in gastroduodenal-<z:e sem="disease" ids="C0017168,C0559234" disease_type="Disease or Syndrome;Finding" abbrv="">esophageal reflux</z:e> and by a carcinogen (N -<z:chebi fb="36" ids="29309">methyl</z:chebi>-N -benzylnitrosamine): group I (50 <z:mp ids='MP_0002169'>wild type</z:mp>), group II (45 p27 heterozygous), and group III (50 p27 knockout) </plain></SENT>
<SENT sid="3" pm="."><plain>The mice were killed 18 to 20 weeks after operation and studied macroscopically and histopathologically </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> developed in 7 (14%) mice in group I, 4 (8.9%) mice in group II, and 13 (26%) mice in group III </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancers</z:e> developed in 30 (60%) mice in group I, 31 (68%) mice in group II, and 43 (86%) mice in group III </plain></SENT>
<SENT sid="6" pm="."><plain>Ten percent of the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> in group I were <z:mp ids='MP_0009308'>adenocarcinomas</z:mp>, as were 16.1% in group II, and 23.3% in group III </plain></SENT>
<SENT sid="7" pm="."><plain>The difference between rates of <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> in groups I and II compared with group III was statistically significant (P =.035), as was true of the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> rates (P =.006) </plain></SENT>
<SENT sid="8" pm="."><plain>The percentage of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> that were <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> was highest in group III, but not significantly different from groups I and II </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: This experimental mouse model of <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> and Barrett- associated <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> is similar to what occurs in human beings and may be useful in developing methods to inhibit <z:e sem="disease" ids="C1608408" disease_type="Neoplastic Process" abbrv="">malignant transformation</z:e> of <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> </plain></SENT>
</text></document>